Literature DB >> 10395688

IFN-gamma mediates a novel antiviral activity through dynamic modulation of TRAIL and TRAIL receptor expression.

L M Sedger1, D M Shows, R A Blanton, J J Peschon, R G Goodwin, D Cosman, S R Wiley.   

Abstract

TNF-related apoptosis-inducing ligand (TRAIL) is able to kill many transformed cells of diverse tissue types. We show that TRAIL is inducible by IFN-gamma, by TNF-alpha, and by infection with human CMV, and has potent antiviral activity in vitro. CMV infection and IFN-gamma also reciprocally modulate TRAIL receptor (TRAIL-R) expression. CMV infection increased the expression of TRAIL-R1 and -R2, whereas IFN-gamma down-regulated the expression of TRAIL-Rs on uninfected fibroblasts. Moreover, IFN-gamma significantly decreased the basal level of NF-kappaB activation, a known survival factor that inhibits apoptosis. Thus, TRAIL selectively kills virus-infected cells while leaving uninfected cells intact, and IFN-gamma potentiates these effects by dynamic modulation of TRAIL and TRAIL-R expression and by sensitizing cells to apoptosis. The regulation of TRAIL and TRAIL-R expression may represent a general mechanism that contributes to the control of TRAIL-mediated apoptosis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10395688

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  72 in total

1.  Reovirus-induced apoptosis is mediated by TRAIL.

Authors:  P Clarke; S M Meintzer; S Gibson; C Widmann; T P Garrington; G L Johnson; K L Tyler
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

2.  Incoming human cytomegalovirus pp65 (UL83) contained in apoptotic infected fibroblasts is cross-presented to CD8(+) T cells by dendritic cells.

Authors:  G Arrode; C Boccaccio; J Lulé; S Allart; N Moinard; J P Abastado; A Alam; C Davrinche
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

3.  Respiratory syncytial virus infection sensitizes cells to apoptosis mediated by tumor necrosis factor-related apoptosis-inducing ligand.

Authors:  Alexander Kotelkin; Elena A Prikhod'ko; Jeffrey I Cohen; Peter L Collins; Alexander Bukreyev
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

4.  The magnitude of the T cell response to a clinically significant dose of influenza virus is regulated by TRAIL.

Authors:  Erik L Brincks; Prajwal Gurung; Ryan A Langlois; Emily A Hemann; Kevin L Legge; Thomas S Griffith
Journal:  J Immunol       Date:  2011-09-21       Impact factor: 5.422

5.  Poxvirus tumor necrosis factor receptor (TNFR)-like T2 proteins contain a conserved preligand assembly domain that inhibits cellular TNFR1-induced cell death.

Authors:  Lisa M Sedger; Sarah R Osvath; Xiao-Ming Xu; Grace Li; Francis K-M Chan; John W Barrett; Grant McFadden
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

Review 6.  CD95 (Fas/APO-1)/CD95L in the gastrointestinal tract: fictions and facts.

Authors:  J Sträter; P Möller
Journal:  Virchows Arch       Date:  2003-02-11       Impact factor: 4.064

7.  Induction of cell death in human immunodeficiency virus-infected macrophages and resting memory CD4 T cells by TRAIL/Apo2l.

Authors:  J J Lum; A A Pilon; J Sanchez-Dardon; B N Phenix; J E Kim; J Mihowich; K Jamison; N Hawley-Foss; D H Lynch; A D Badley
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

Review 8.  Hepatitis C virus infection and apoptosis.

Authors:  Richard Fischer; Thomas Baumert; Hubert-E Blum
Journal:  World J Gastroenterol       Date:  2007-09-28       Impact factor: 5.742

9.  Streptococcus pneumoniae-induced caspase 6-dependent apoptosis in lung epithelium.

Authors:  Bernd Schmeck; Ralph Gross; Phillipe Dje N'Guessan; Andreas C Hocke; Sven Hammerschmidt; Tim J Mitchell; Simone Rosseau; Norbert Suttorp; Stefan Hippenstiel
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

Review 10.  The TRAIL to viral pathogenesis: the good, the bad and the ugly.

Authors:  Nathan Cummins; Andrew Badley
Journal:  Curr Mol Med       Date:  2009-05       Impact factor: 2.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.